Waterloo Capital L.P. Takes $219,000 Position in Medtronic PLC $MDT

Waterloo Capital L.P. purchased a new stake in shares of Medtronic PLC (NYSE:MDT) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,513 shares of the medical technology company’s stock, valued at approximately $219,000.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Coldstream Capital Management Inc. boosted its holdings in shares of Medtronic by 4.1% in the 2nd quarter. Coldstream Capital Management Inc. now owns 52,457 shares of the medical technology company’s stock valued at $4,573,000 after buying an additional 2,070 shares during the period. Boston Research & Management Inc. lifted its holdings in Medtronic by 4.1% in the second quarter. Boston Research & Management Inc. now owns 50,497 shares of the medical technology company’s stock worth $4,401,000 after acquiring an additional 1,996 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Medtronic by 1.5% in the second quarter. Charles Schwab Investment Management Inc. now owns 8,160,266 shares of the medical technology company’s stock worth $711,330,000 after acquiring an additional 118,314 shares during the last quarter. AlphaCore Capital LLC boosted its stake in Medtronic by 5.6% in the second quarter. AlphaCore Capital LLC now owns 6,165 shares of the medical technology company’s stock valued at $535,000 after acquiring an additional 326 shares during the period. Finally, Mufg Securities Americas Inc. grew its holdings in shares of Medtronic by 25.2% during the second quarter. Mufg Securities Americas Inc. now owns 28,425 shares of the medical technology company’s stock valued at $2,478,000 after purchasing an additional 5,727 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on MDT. Leerink Partners set a $120.00 price target on Medtronic and gave the stock an “outperform” rating in a report on Wednesday, November 19th. Citigroup increased their target price on Medtronic from $101.00 to $112.00 and gave the stock a “buy” rating in a research report on Tuesday, October 7th. Piper Sandler reissued a “neutral” rating on shares of Medtronic in a report on Friday, November 14th. Sanford C. Bernstein set a $111.00 price objective on shares of Medtronic in a report on Wednesday, November 19th. Finally, Barclays lifted their price objective on shares of Medtronic from $109.00 to $111.00 and gave the company an “overweight” rating in a research report on Thursday, November 20th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and twelve have assigned a Hold rating to the stock. Based on data from MarketBeat, Medtronic has a consensus rating of “Moderate Buy” and an average price target of $109.72.

Medtronic Price Performance

Shares of MDT opened at $105.32 on Wednesday. Medtronic PLC has a one year low of $79.29 and a one year high of $105.60. The stock’s fifty day moving average is $95.46 and its 200-day moving average is $91.29. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.50 and a current ratio of 2.01. The firm has a market capitalization of $135.09 billion, a price-to-earnings ratio of 29.01, a price-to-earnings-growth ratio of 2.42 and a beta of 0.77.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. The firm had revenue of $8.96 billion during the quarter, compared to analyst estimates of $8.86 billion. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. Medtronic’s revenue was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts anticipate that Medtronic PLC will post 5.46 EPS for the current year.

Insider Activity

In other news, EVP Harry Skip Kiil sold 8,605 shares of the stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total value of $788,045.90. Following the completion of the transaction, the executive vice president directly owned 35,615 shares in the company, valued at $3,261,621.70. This trade represents a 19.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.26% of the stock is owned by company insiders.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.